Losartan vs Valsartan

Both losartan and valsartan effectively lower blood pressure, but their clinical evidence profiles differ. Valsartan has stronger evidence in heart failure, having demonstrated reduced hospitalizations in the Val-HeFT trial and non-inferiority to captopril post-myocardial infarction in VALIANT ^[2]. Losartan demonstrated renal protective benefits in the RENAAL trial for patients with type 2 diabetic nephropathy, establishing it as a preferred ARB for kidney protection ^[3]. For blood pressure reduction, meta-analyses suggest valsartan at 160 mg may achieve slightly greater systolic blood pressure reduction (approximately 2–3 mmHg more) compared to losartan 100 mg ^[1]. Losartan has a unique property among ARBs: it mildly lowers uric acid levels (by 20–25%), which may benefit patients with concurrent gout ^[4]. Both achieve 24-hour blood pressure control with once-daily dosing in most patients.

ARBs as a class are among the best-tolerated antihypertensive medications, and both losartan and valsartan have side-effect profiles similar to placebo in clinical trials ^[1]. Common adverse effects include dizziness (2–4%), upper respiratory infection symptoms, and fatigue. Neither drug causes the dry cough associated with ACE inhibitors. Hyperkalemia is a class risk, occurring in 1–3% of patients, particularly those with renal impairment or taking potassium-sparing diuretics ^[2]. Valsartan was associated with a recall in 2018–2019 due to NDMA contamination in certain generic formulations, though current supplies have been cleared by the FDA ^[3]. Losartan's uricosuric effect can rarely precipitate uric acid kidney stones in susceptible individuals. Both drugs are contraindicated in pregnancy (Category D — second and third trimesters) due to risk of fetal renal damage ^[1].

Both losartan and valsartan are available as inexpensive generics. Generic losartan 50 mg (30 tablets) costs approximately $4–10 at major pharmacies ^[3]. Generic valsartan 160 mg (30 tablets) costs $8–20, slightly more than losartan due to fewer generic manufacturers. Brand-name Cozaar and Diovan cost $200–350/month but are rarely prescribed. Both are covered by most insurance formularies at the lowest copay tier. Combination formulations with hydrochlorothiazide (losartan/HCTZ and valsartan/HCTZ) are also available as generics at similar price points.

Both medications are taken once daily. Losartan is available in 25, 50, and 100 mg tablets, with a typical dose of 50–100 mg/day ^[1]. Valsartan comes in 40, 80, 160, and 320 mg tablets, with doses of 80–320 mg/day ^[2]. Neither requires food for absorption, though valsartan bioavailability decreases by about 40% with food. Both can be taken at any time of day. Losartan has a shorter half-life (6–9 hours) but its active metabolite EXP 3174 extends activity to 24 hours ^[3]. Valsartan has a half-life of 6 hours but achieves sustained AT1 receptor blockade. Neither requires renal dose adjustment for mild to moderate kidney disease.

Both losartan and valsartan are effective ARBs for blood pressure control. Losartan may be preferred for patients with type 2 diabetic nephropathy (based on RENAAL trial evidence), concurrent hyperuricemia or gout (due to its uric acid–lowering effect), or cost-sensitive situations ^[3][4]. Valsartan may be the better choice for patients with heart failure (based on Val-HeFT evidence), post-myocardial infarction patients (VALIANT trial), or those needing more potent blood pressure reduction ^[2]. For uncomplicated hypertension without these comorbidities, either drug is an appropriate choice. Your healthcare provider can help determine which ARB best fits your clinical profile.